Cédric Leroy

机构：Idorsia (Switzerland), Idorsia Pharmaceuticals Ltd (Switzerland) · ORCID：0000-0002-0104-6591

发表论文 68 篇 · 总被引 1341 次 · h-index 15

代表论文

• The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα (2017 · Nature · 被引 156)
• Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition (2016 · Breast Cancer Research · 被引 130)
• Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer (2018 · EMBO Molecular Medicine · 被引 116)
• Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R (2013 · Oncogenesis · 被引 66)
• Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases (2014 · Oncogene · 被引 65)
• SLAP displays tumour suppressor functions in colorectal cancer via destabilization of the SRC substrate EPHA2 (2014 · Nature Communications · 被引 55)